Stability-Indicating Reverse Phase HPLC Method for the Determination of Cefazolin
Purpose: The aim of the present study was to establish the inherent stability of cefazolin through stress studies under a variety of ICH recommended test conditions and, also to develop a stability indicating
assay. Methods: A stability-indicating HPLC assay method was developed and validated for cefazolin using an isocratic RP-HPLC method which employed an SS Wakosil II- C18 column (250 mm × 4.6 mm i.d., 5 μm) with a mobile phase consisting of phosphate buffer (pH 6.8) and methanol (5:2 v/v), and UV detection at 254 nm at a flow rate of 1 ml/min. The stress testing of cefazolin was carried out under acidic, alkaline, neutral, oxidation and thermal conditions. Results: The drug peak was well resolved from the peaks of the degradation products. The proposed method was validated for sensitivity, selectivity, linearity, accuracy, precision and solution stability. From the degradation studies it was found that the drug was thermally stable but unstable in acidic, alkaline, neutral and oxidative conditions. The response of drug was linear in the concentration Range of 1 - 50 μg/ml with the number of theoretical plates, and tailing factor being 1341 and 1, respectively. Limit of detection and limit of quantification were 0.1 and 0.2, μg/ml respectively while recovery ranged from 95 - 100%. Method precision and precision of the system were within the limits of acceptance criteria. Conclusion: This study presents a simple and validated stability-indicating HPLC method for the estimation of cefazolin in the presence of degradation products. The developed method is specific, accurate, precise and robust. All the degradation products formed during forced degradation studies were well separated from the analyte peak.
Keywords: Cefazolin; Stability-indicating assay; Reversed-phase HPLC
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.